Artículos por temáticas

Effects of aerobic exercise on cognitive function and quality of life in patients with Alzheimer's disease: a systematic review and meta-analysis

Yang L, Yuan Z, Peng C.

BMJ Open. 2025 Jan 11;15(1):e090623. doi: 10.1136/bmjopen-2024-090623.

Connecting dots: Preclinical foundations to clinical realities of PDE4 inhibitors in Alzheimer's disease

Kumari S, Bagri K, Deshmukh R.

Inflammopharmacology. 2025 Feb;33(2):593-603. doi: 10.1007/s10787-024-01638-1. Epub 2025 Jan 14.

Shedding light on microglial dysregulation in Alzheimer's disease: exploring molecular mechanisms and therapeutic avenues

Bhardwaj V, Kumari S, Dhapola R, Sharma P, Beura SK, Singh SK, Vellingiri B, HariKrishnaReddy D.

Inflammopharmacology. 2025 Feb;33(2):679-702. doi: 10.1007/s10787-024-01598-6. Epub 2024 Nov 28.

PDE4D inhibitors: Opening a new era of PET diagnostics for Alzheimer's disease

Shi L, Wang X, Si H, Song W.

Neurochem Int. 2025 Jan;182:105903. doi: 10.1016/j.neuint.2024.105903. Epub 2024 Dec 6.

Pre-treatment subjective sleep quality as a predictive biomarker of tDCS effects in preclinical Alzheimer's disease patients: Secondary analysis of a randomised clinical trial

Lu H, Ni X, Man Chan SS, Cheng CPW, Chan W, Lam LCW.

PLoS One. 2025 Jan 28;20(1):e0317700. doi: 10.1371/journal.pone.0317700. eCollection 2025.

Drugs repurposing in the experimental models of Alzheimer's disease

Joodi SA, Ibrahim WW, Khattab MM.

Inflammopharmacology. 2025 Jan;33(1):195-214. doi: 10.1007/s10787-024-01608-7. Epub 2025 Jan 3.

Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment

Jang YJ, Kang SJ, Park HS, Lee DH, Kim JH, Kim JE, Kim DI, Chung CH, Yoon JK, Bhang SH.

J Nanobiotechnology. 2025 Feb 10;23(1):99. doi: 10.1186/s12951-025-03109-3.

Ellagic Acid: A Green Multi-Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer's Disease

Alfei S, Zuccari G.

Int J Mol Sci. 2025 Jan 20;26(2):844. doi: 10.3390/ijms26020844.

Progress in the treatment of Alzheimer's disease based on nanosized traditional Chinese medicines

Song D, Zhang J, Hu X, Liu X.

J Mater Chem B. 2025 Jan 29;13(5):1548-1572. doi: 10.1039/d4tb02062f.

Biomarker treatment effects in two phase 3 trials of gantenerumab

Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, Delmar P, Scelsi MA, Gobbi S, Silvestri E, Barakovic M, Napolitano A, Galli C, Abaei M, Blennow K, Barkhof F.

Alzheimers Dement. 2025 Feb;21(2):e14414. doi: 10.1002/alz.14414. Epub 2025 Jan 30.

Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer's Disease

Abualassal Q, Abudayeh Z, Sirhan A, Mkia A.

Molecules. 2025 Jan 26;30(3):555. doi: 10.3390/molecules30030555.

Myeloperoxidase as a therapeutic target for oxidative damage in Alzheimer's disease

Rivera Antonio AM, Padilla Martínez II, Torres-Ramos MA, Rosales-Hernández MC.

J Enzyme Inhib Med Chem. 2025 Dec;40(1):2456282. doi: 10.1080/14756366.2025.2456282. Epub 2025 Feb 14.

The regulation of miRNAs using curcumin and other polyphenols during the prevention and treatment of Alzheimer's disease

Wang X, Zhang S, Li Y, Zhang Y.

Hum Mol Genet. 2025 Jan 29;34(2):117-127. doi: 10.1093/hmg/ddae154.

Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): results of a randomised controlled trial

Forstmeier S, Maercker A, Bohli L, Savaskan E, Roth T.

Aging Ment Health. 2025 Feb;29(2):359-368. doi: 10.1080/13607863.2024.2393748. Epub 2024 Aug 20.

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K.

J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1.